The present invention aims to provide an iminopyridine derivative compound having an α
1D
adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.
The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
The present invention provides compounds having formula (I):
and pharmaceutically acceptable derivatives thereof, wherein R
1
-R
4
, n, p, A, B, D, E, L and AR
1
are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
The present invention aims to provide an iminopyridine derivative compound having an α
1D
adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.
The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.